pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Approval · news · pharmadog
← back to Approval
News · Approval
1,123
stories
7d
Merck, Daiichi end plans to seek speedy approval of lung cancer ADC
biopharma dive
8d
AbbVie wins FDA approval for Parkinson’s drug from $8.7B Cerevel takeover
biospace
8d
Merck, Daiichi Sankyo retract accelerated approval request for lung cancer ADC
biospace
8d
Merck, Daiichi scrap FDA application for B7-H3 ADC in lung cancer
endpoints
8d
Mirum posts phase 3 hepatitis win for ‘commercially differentiated’ challenger to Gilead, Vir
fiercebiotech
8d
Precision Neuroscience taps $250M in Series D funding for brain-computer interface
fiercebiotech
8d
Kodiak's stock doubles as resurrected eye disease drug matches Eylea in phase 3
fiercebiotech
8d
STAT+: Once described as obesity medicines for ‘patients,’ GLP-1s are increasingly lifestyle drugs for ‘customers’
stat
8d
Milestone Sanfilippo nod helps Ultragenyx regroup after tough Angelman defeat
biospace
8d
6 immunology targets to sustain a mammoth I&I market
biospace
8d
Merck, Daiichi pull lung cancer filing after FDA pushback deals another blow to $4B deal
fiercebiotech
8d
Asia-Pacific Roundup: Indian government approves adverse event monitoring plan for transplantation products
raps
9d
AbbVie's next-gen dopamine therapy for Parkinson's gets FDA approval
endpoints
10d
FDA approves Mirum’s drug for ultra-rare soft tissue disease
endpoints
10d
STAT+: Licensing deals on generic versions of Roche flu drug aimed at preparing for pandemic
stat
10d
Pharma industry asks FDA for more details on when one trial is enough
endpoints
10d
STAT+: Lilly wins approval for once-weekly insulin shot
stat
10d
Opinion: FDA commissioner nominee Heidi Overton is ignoring the science on abortion drug
stat
10d
Adicet Bio CAR-T sparks lupus remissions in early trial as ‘new era’ of autoimmune treatment approaches
fiercebiotech
10d
Novo pursues long-acting obesity drugs; Acadia slumps on Alzheimer’s data
biopharma dive
11d
Merck expands Welireg's use to broader set of kidney cancer patients
endpoints
11d
Grail multicancer detection test wins FDA advisers’ backing
biopharma dive
11d
US senators grill FDA nominee Overton on ability to ‘stand up’ to Trump
biospace
11d
Elevar wins first FDA approval with second-line drug for bile duct cancer
endpoints
11d
Chutes & Ladders—Travere chief makes way for former Amicus CEO
fiercebiotech
11d
Trump's FDA pick Heidi Overton calls vaccines, mifepristone safe and effective in confirmation hearing
fiercebiotech
11d
STAT+: Kyverna’s cell therapy shows lasting autoimmune benefit
stat
11d
Kyverna steps closer to FDA-first CAR T for an autoimmune condition with durability data
biospace
11d
Eli Lilly’s weekly insulin shot cleared by FDA, setting up another front in Novo rivalry
biospace
12d
China’s Henlius carves out $440M T-cell engager deal with Amberstone
fiercebiotech
← prev
page 3 of 38
next →
